AnaptysBio (NASDAQ: ANAB) board member receives options, RSUs grant

Rhea-AI Filing Summary

AnaptysBio, Inc. director Renton Hollings received new equity awards on January 6, 2026. He was granted a stock option for 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share, with no purchase price for the grant itself. This option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, so long as he continues to provide service on each vesting date.

He was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs vest as to 100% of the 4,000 units on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service through that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RENTON HOLLINGS

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$43.91	01/06/2026		A		5,500		(1)	01/05/2036	Common Stock	5,500	$0	5,500	D
Restricted Stock Unit	(2)	01/06/2026		A		4,000		(3)	(3)	Common Stock	4,000	$0	4,000	D

Explanation of Responses:

1. The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

3. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Eric Loumeau, Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did AnaptysBio (ANAB) director Renton Hollings receive?

On January 6, 2026, director Renton Hollings received two equity awards: a stock option for 5,500 shares of common stock at an exercise price of $43.91 per share, and 4,000 restricted stock units (RSUs), each RSU representing one share of common stock for no cash consideration upon settlement.

How do the new stock options for AnaptysBio (ANAB) director vest?

The 5,500-share stock option granted to Renton Hollings vests in monthly installments. Specifically, 1/12 of the total shares vest each month, beginning on February 6, 2026, and continue until the option is fully vested, provided he continues to serve the company on each vesting date.

What are the vesting terms of the 4,000 RSUs reported for AnaptysBio (ANAB)?

The 4,000 RSUs granted to Renton Hollings vest as to 100% of the units on the date of AnaptysBio’s 2027 annual meeting of shareholders. Vesting is conditioned on his continued service to the company through that meeting date.

Does Renton Hollings pay anything to receive the RSUs from AnaptysBio (ANAB)?

No. Each restricted stock unit is described as a right to receive 1 share of AnaptysBio common stock upon settlement for no consideration, meaning there is no cash payment required when the RSUs settle into shares.

Are the reported AnaptysBio (ANAB) equity awards held directly or indirectly by the director?

The filing indicates that both the stock option (5,500 shares) and the 4,000 RSUs are held with direct (D) ownership by director Renton Hollings, with no separate entity or indirect ownership structure noted.

What role does Renton Hollings have at AnaptysBio (ANAB) according to this Form 4?

The report identifies Renton Hollings as a director of AnaptysBio, Inc. It does not list him as an officer or 10% owner in this filing.